Juvenescence and Lygenesis - great article and video16 Aug 2020 21:59
https://www.fightaging.org/archives/2019/03/video-of-investor-jim-mellon-presenting-at-abundance-360-summit-2019/
The market alone for Lygenesis is 7 million people who have end-stage liver disease x $100,000 cost per person = $700 billion. Even if we assume only 1% take up the market is still $7 billion. At that's 30% of Juvenescence, not to mention everything else in the FFWD portfolio.
Food for thought!
'In the last few minutes I wanted to talk about Lygenesis. This is the first company that will be in humans, in the first quarter of next year. One year away - it is not very far. It will be in sick patients, so we can see immediately in a phase 2 trial whether it works or not. The idea is to take a cadaver liver, donated by someone, probably someone who fell off a motorbike, unfortunately, and divide it into 75 pieces. Those 75 pieces are implanted into 75 patients, and put it into a lymph node, and hope that the liver fully vascularizes and works and takes over from the patient's failing liver. There are plenty of people in the work who have failing livers. It costs $700,000 for a liver transplant here in the United States. It takes fifteen hours, and has a high mortality rate associated with it. Lygenesis has a twenty minute outpatient procedure, and it will cost less than $100,000 dollars to do. It expands the number of potential liver transplants, and there are seven million people in the US and Europe who have failing livers to the point at which it is going to kill them.'
Sign In
Follow the stocks
